Is POTS Autoimmune? What the Antibody and Hashimoto's Research Shows

What Would Make POTS an Autoimmune Disease?

Some autoimmune activity is normal in everyone. A 2001 review describes autoimmune disease as an aberration of that normal process, with "the final common pathway being the loss of normal self-tolerance." In the clinic's words, autoimmunity is a response "so big that we're attacking stuff it shouldn't even attack."

No study we reviewed shows that POTS as a whole is autoimmune. The evidence is a set of small antibody studies, a larger study that didn't confirm them, single-clinic counts of other diagnoses and one negative IVIG trial. There is a rare condition where the immune system clearly drives autonomic failure: autoimmune autonomic ganglionopathy (AAG), "an acquired immune-mediated disorder that leads to autonomic failure," tied to antibodies against the ganglionic nicotinic acetylcholine receptor. AAG is its own diagnosis, separate from POTS. AAG causes severe autonomic failure, while POTS by definition has no drop in blood pressure on standing.

A 2021 case report describes an immune-mediated form of neuropathic POTS that responded to immunoglobulin; neuropathic POTS covers those cases. For positive autoimmune bloodwork after COVID, POTS and Long COVID covers whether it's a driver or a downstream result.

Do People With POTS Have Autoimmune Antibodies?

Some small studies found receptor antibodies in people with POTS. In a 2017 study of 17 people with POTS, 8, 11 and 12 had autoantibodies that activated the α1, β1 and β2 adrenergic receptors, the receptors adrenaline and noradrenaline act on. A 2018 study found angiotensin II type 1 receptor antibody activity in 12 of 17 people with POTS. A 2019 lab test of antibody activity, in 37 people with POTS and 61 controls, found β1 receptor activity in 52% of the POTS group and 2% of controls, and its authors called this "a possible autoimmune contribution to POTS pathophysiology." A 2021 study found M4 muscarinic receptor autoantibodies in 19 of 34 people with POTS.

The largest study cuts against all of these. In 2022, 116 people with POTS and 81 controls were tested with standard lab methods for antibodies to 11 receptors, including adrenergic, muscarinic and angiotensin II receptors, and antibody levels against every receptor tested "were not significantly different between controls and patients with POTS." Antibodies show up in some people with POTS, and the largest of these studies couldn't use them to tell POTS apart from controls.

Can Hashimoto's Cause POTS?

Hashimoto's shows up more often in POTS, and no study we found shows that it causes POTS. In a 2015 study of 100 patients at one clinic, 90% of them women, Hashimoto's was the most common autoimmune disorder: 11%, compared with up to 2% in the general population (odds ratio 6.1). That design counts how often the 2 conditions occur together, so it can't tell which came first or whether one drives the other. Those comparisons used published population rates rather than a matched control group, and they weren't adjusted for sex, which matters when 90% of the patients are women. Your physician manages the thyroid side, including checking that levels are in range.

The same study found rheumatoid arthritis in 4% (up to 1% in the general population) and lupus in 2% (up to 0.12%). Celiac disease is contested: a 2016 study found biopsy-proven celiac disease in 4 of 100 people with POTS against 1% locally (odds ratio 4.1), while the 2015 study found only a "nonsignificant trend." A 2023 meta-analysis that adjusted for sex put the pooled celiac ratio at 2.75. It called its exploratory prevalence ratios for lupus, Sjögren's syndrome and antiphospholipid syndrome "very large," but it drew on only 4 studies, and "all studies were assessed as being at high risk of bias."

The overlap also runs the other way. A 2025 review calls dysautonomia "one of the common and under-recognized comorbidities of a wide variety of systemic disease," autoimmune disorders included. That matches what our team sees: many patients arrive with an autoimmune diagnosis and dysautonomia at the same time.

Finding	Patients	Result	Status
Adrenergic receptor antibodies	17 with POTS (2017); 37 with POTS and 61 controls (2019)	8, 11 and 12 of 17 positive; β1 activity in 52% vs 2%	Small studies; not confirmed in 2022
Angiotensin II type 1 receptor antibodies	17 with POTS (2018)	12 of 17 positive	Small study; not confirmed in 2022
M4 muscarinic antibodies	34 with POTS (2021)	19 of 34 positive	Small study; not confirmed in 2022
Receptor antibodies with standard lab methods	116 with POTS and 81 controls (2022)	No difference from controls	Null result
Hashimoto's	100 at 1 clinic (2015)	11% vs up to 2% (odds ratio 6.1)	Co-occurrence only
Celiac disease	100 with POTS (2016); 100 at 1 clinic (2015)	4 of 100 vs 1% (odds ratio 4.1); nonsignificant trend	Contested
IVIG vs albumin, randomized	30 with POTS (2024)	COMPASS-31 change didn't differ (p = 0.629)	Randomized; negative

Does IVIG or Immunotherapy Help POTS?

The one randomized trial we found was negative. In iSTAND, published in 2024, 30 people with POTS who met criteria suggesting autoimmunity were randomized to IVIG (16) or albumin (14), and 27 completed treatment. Change in COMPASS-31, a 31-question survey of autonomic symptoms, "did not differ between groups" (p = 0.629). The IVIG group had a higher response rate, 46.7% against 38.5% with albumin, but the difference wasn't statistically significant.

A smaller 2023 series points the other way. All 7 patients treated with subcutaneous immunoglobulin or plasmapheresis improved, "with an average 50% reduction in COMPASS 31 score." That series had no control group, and the albumin group in iSTAND shows that people improve on a comparison treatment too. So far, the only reports of benefit come from small uncontrolled series, and the one randomized trial didn't show IVIG beating albumin. That's the ceiling on immunotherapy for POTS right now. Our team doesn't advise starting, stopping or changing any medication; that's the prescriber's call.

Why Would the Immune and Autonomic Systems Overlap?

Our team's model treats the immune system as one of the body's outputs. Most functions in the body start with an input, the nervous system processes it, and an output follows. Muscle movement is the output most people picture, and mobilizing the immune system is another.

In the clinic's view, the immune and autonomic systems "work in tandem 'cause it's all an integrated system that works together." When the immune output runs too high, it can turn on the body's own tissue. When it runs too low, defenses drop. As the clinic puts it, "a lot of people will experience immune compromise in either direction as part of what they're dealing with." This is the clinic's model, and the studies above don't test it.

Balanced Over-response Under-response

Replay

MCAS and dysautonomia covers how mast cells fit into this overlap.

What Should You Test If You Have POTS and an Autoimmune Diagnosis?

The autoimmune diagnosis has its own workup with your physician. Receptor antibody tests are commercially available, but the 2022 study, which used one, concluded that these tests "are not useful for establishing the role of autoimmunity in POTS," so a positive result doesn't confirm an autoimmune cause. The autonomic side can be measured directly: our team tests how heart rate, blood pressure and brain blood flow respond when you stand, to see whether brain blood flow holds steady when you're upright and what your heart and blood pressure are doing to protect it. If numbness, burning or sweating changes are part of the picture, small fiber neuropathy and POTS explains how nerve damage can feed dysautonomia.

POTS and Autoimmunity: FAQ